Everything is theoretically impossible, until it is done.

Robert Heinlein

Mote's disruptive technology draws together the disciplines of genome editing, in vitro evolution and synthetic biology.

We are developing a suite of highly engineered proteins and delivery systems to enable safe, predictable down-to-the-basepair editing of the genome in adult humans. With essentially zero off-target effects and predictable insertion, deletion and alteration of genomic sequences, these tools offer therapeutic and preventative potentials far beyond CRISPR.